Pathology of Triple-Negative Breast Cancer: Clinical Implications and Therapeutic Strategies

Triple-negative breast cancer (TNBC) represents a unique subtype characterized by the absence of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression. This track will delve into the intricate pathology of TNBC, exploring its clinical implications and therapeutic strategies. Attendees will gain insights into the aggressive nature of TNBC, its distinct molecular features, and the challenges associated with diagnosis and treatment. Discussion will focus on emerging biomarkers, novel targeted therapies, and immunotherapy approaches. By understanding the underlying pathology of TNBC, participants will be equipped to optimize patient management, improve prognostic evaluation, and contribute to the development of personalized therapeutic interventions.

  • Molecular Subtypes and Biomarkers in Triple-Negative Breast Cancer
  • Therapeutic Strategies and Future Directions for Triple-Negative Breast Cancer

Related Conference of Pathology of Triple-Negative Breast Cancer: Clinical Implications and Therapeutic Strategies

December 14-15, 2023

5th International Conference on Oncology and Cancer

Rome, Italy
February 22-23, 2024

14th World Congress on Breast Cancer

Zurich, Switzerland
March 18-19, 2024

5th Global Summit on Oncology and Hematology

Zurich, Switzerland
March 21-22, 2024

8th Global Meeting on Oncology and Radiology

Paris, France
April 18-19, 2024

24th World Congress on Cancer and Diagnostics

Dubai, UAE

Pathology of Triple-Negative Breast Cancer: Clinical Implications and Therapeutic Strategies Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in